Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Axsome Therapeutics (AXSM) PT Raised to $200 at Truist Securities

February 18, 2025 1:13 PM EST

Truist Securities analyst Joon Lee raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $200.00 (from $190.00) while maintaining a Buy rating.

The analyst comments "4Q24. No surprises to results preannounced in January. More importantly, Ph3 study of solriamfetol in... More